What is Pancreatic Cancer?
Pancreatic Cancer is a disease with a high unmet medical need. In 2017, an estimated 53,070 adults in the United States will be diagnosed with Pancreatic Cancer. The majority of Pancreatic Cancer cases are diagnosed late, at which point the disease is already locally advanced or metastatic.
The disease accounts for about 3 percent of all cancers in the US and is the fourth leading cause of cancer death in men and women according to the American Cancer Society.
BPGbio’s (BERG) Pancreatic Cancer drug candidate (BPM 31510) Received FDA Orphan-Drug Designation in November 2017.
Clinical Trials
The Phase 2 clinical trial for BPGbio’s (BERG) Pancreatic Cancer drug candidate (BPM 31510) is complete.
For more information about BPGbio’s (BERG) BPM31510 Pancreatic Cancer trial, please click here.